Agonist of peroxisome proliferator-activated receptor gamma (PPAR-  ): a new compound with potent gastroprotective and ulcer healing properties

Author： Brzozowski Tomasz  

Publisher： VSP

ISSN： 1568-5608

Source： Inflammopharmacology, Vol.13, Iss.1-3, 2005-08, pp. : 317-330

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (&ggr;) Agonist

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 2, 2012-02 ,pp. : 87-97

Bentham Science Publishers

Access to resources Recommend Favorite

Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat

By Konturek P.C.   Brzozowski T.   Kania J.   Konturek S.J.   Kwiecien S.   Pajdo R.   Hahn E.G.  

European Journal of Pharmacology, Vol. 472, Iss. 3, 2003-07 ,pp. : 213-220

Elsevier

Access to resources Recommend Favorite

Role of peroxisome proliferator-activated receptor  activation in gastric mucosal ulcer healing

By Slomiany B. L.   Slomiany A.  

Inflammopharmacology, Vol. 9, Iss. 4, 2001-08 ,pp. : 347-359

VSP

Access to resources Recommend Favorite

The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 2, 2013-06 ,pp. : 175-183

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite